Cryptocurrency has proved a controversial addition to world finance, but there’s no denying that it’s making its presence felt. There are advantages and disadvantages to using crypto, but for those who are comfortable with this alternative form of money, you want to be able to use it in all relevant areas of your life. For those with an interest in longevity and healthy aging, that may be a little easier thanks to Rejuve.AI.
Rejuve.AI is a longevity company that operates in the SingularityNET ecosystem. It has a particular focus on AI, but blockchain also forms a prominent part of its methodology and product. It’s all part of a plan to try to make healthy aging more accessible to a wider population of people.
The Rejuve.AI app allows you to upload your personal biological, medical and lifestyle data gathered from wearables, lab tests or even surveys, and then its AI analyzes it to provide insights and advice. To help incentivize you to share this sometimes sensitive information, you’ll be awarded special RJV crypto tokens in return. These tokens can be spent with a range of Rejuve.AI’s partner organizations.
What kind of partner organizations are involved? The newest additions include some big names in longevity and healthcare. GlycanAge is the creator of a pioneering test for biological age using compounds known as glycans, Peptide Bioregulator produces a range of longevity supplements, and the Vita Authentica wellness platform has become a major player in Canada. Now all three of them are accepting RJV crypto tokens as a way to access their sometimes costly products.
It just goes to show the breadth of crypto’s reach and how it has a part to play in longevity research. Not all consumers are going to be comfortable with it, but for those who are, the opportunity to use crypto-based rewards represents an exciting step forward and may encourage even more people to participate in this kind of research and development.
Data gathered by Rejuve.AI isn’t just useful for the individual trying to assess their own health. It can also be used for wider research purposes, allowing for the development of new drugs and therapies based on a broader sample population, each with their own individualized health situation. To facilitate this, a sister company to Rejuve.AI, Rejuve.Bio, has been formed to trial and hopefully commercialize these more experimental therapies.
